FOXP3 and systemic sclerosis: As increases in peripheral Foxp3+ Tregs have also been reported for patients with cancer [38], [39], primary Sjögren’s Syndrome and rheumatoid arthritis [40], psoriasis [41] and systemic sclerosis [42], we hypothesize that a non-specific chronic inflammatory mediator can cause this effect.